Should the ApoE genotype be a covariate for clinical trials in Alzheimer disease?

Alzheimer's Research and Therapy

Volumn 2, Issue 3, 2010, Pages

  Farlow, Martin R ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; BAPINEUZUMAB; CARRIER PROTEIN; DONEPEZIL; GALANTAMINE; LIPID; PLACEBO; RIVASTIGMINE; ROSIGLITAZONE; TACRINE;

ALZHEIMER DISEASE; BRAIN EDEMA; CELL ACTIVATION; GENOTYPE; HUMAN; MICROGLIA; MILD COGNITIVE IMPAIRMENT; NEUROFIBRILLARY TANGLE; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

EID: 81755170928     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt39     Document Type: Review

References (15)

1. Apolipoprotein E-episilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. Premkumar DR, Cohen DL, Hedera P, Friedland RP, Kalaria RN, Am J Pathol 1996 148 2083 2095 8669492
2. High frequency of apolipoprotein E epsilo4 allele in young individuals with very mild Alzheimer's disease-related neurofibrillary changes. Ghebremedhin E, Schultz C, Braak E, Braak H, Exp Neurol 1998 153 152 155 (Pubitemid 28452307)
3. Impact of APOE in mild cognitive impairment. Farlow MR, He Y, Tekin S, Xu J, Lane R, Charles HC, Neurology 2004 63 1898 1901 (Pubitemid 39532387)
4. Increased levels of CSF phosphorylated tau in apolipoprotein E epsilon4 carriers with mild cognitive impairment. Buerger K, Teipel SJ, Zinkowski R, Sunderland T, Andreasen N, Blennow K, Ewers M, DeBernardis J, Shen Y, Kerkman, Du Y, Hampel H, Neuroscience Letters 2005 391 48 50 10.1016/j.neulet.2005.08.030 16165272 (Pubitemid 41642676)
5. Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. Linton MF, Gish R, Hubl ST, Butler E, Esquivel C, Bry WI, Boyles JK, Wardell MR, Young SG, J Clin Invest 1991 88 207 281 10.1172/JCI115288
6. Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides. Tokuda T, Calero M, Matsubara E, Vidal R, Kumar A, Permanne B, Zlokovic B, Smith JD, Ladu MJ, Rostagno A, Frangione B, Ghiso J, Biochem J 2000 348 359 365 10.1042/0264-6021:3480359 10816430 (Pubitemid 30345209)
7. Microglial activation in Alzheimer disease: association with APOE genotype. Egensperger R, Kosel S, von Eitzen U, Graeber MB, Brain Pathol 1998 8 439 447 (Pubitemid 28308843)
8. Apolipoprotein E4 allele as a predictor of cholinergic defficits and treatment outcome in Alzheimer's disease. Poirier J, Delisle M-C, Quirion R, Aubert I, Farlow M, Lahiri D, Hui S, Bertrand P, Nalbantoglu J, Gilfix BM, Gauthier S, Proc Natl Acad Sci USA 1995 92 12260 12264 10.1073/pnas.92.26.12260 8618881 (Pubitemid 26014050)
9. Presence or absence of at least one e4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer's disease. Rigaud A-S, Traykov L, Latour F, Couderc R, Moulin F, Forette F, Pharmacogenetics 2002 12 415 420 10.1097/00008571-200207000-00009 (Pubitemid 34816421)
10. Relationship between the efficacy of rivastigmine and apolipoprotein E (4) in patients with mild to moderately severe Alzheimer disease. Blesa R, Aguilar M, Casanova JP, Boada M, Martinez S, Alom J, Hernandez de la Hoz C, Sancho J, Fernandez O, Gil-Neciga E, Masso JFM, Alzheimer Dis Assoc Dis 2006 20 248 254 10.1097/01.wad.0000213880.93665.c7 (Pubitemid 44900938)
11. APOE genotype: no influence on galantamine treatment efficacy or on rate of decline in Alzheimer's disease. Aerssens J, Raeymaekers P, Lilienfeld S, Geerts H, Konings F, Parys W, Dement Geriatr Cogn Disord 2001 12 69 77 10.1159/000051238 11173877 (Pubitemid 32149710)
12. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5791 as a model of safety. Roses AD, Neuropsychopharmacology 2009 34 6 17 10.1038/npp.2008.153 18923406
13. Drugs in Clinical Trials-Rosiglitazone. Alzforum, http://www.alzforum. org/drg/drc/detail.asp?id=116
14. Vitamin E and donepezil for the treatment of mild cognitive impairment. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ, for the Alzheimer's Disease Cooperative Study Group, N Engl J Med 2005 352 2379 2388 10.1056/NEJMoa050151 15829527
15. A phase 2 multiple ascending dose trial of Bapineuzumab in mild to moderate Alzheimer disease. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M, Bapineuzumab 201 Clinical Trial Investigators, Neurology 2009 73 2061 2070 10.1212/WNL. 0b013e3181c67808